[EN] COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE<br/>[FR] COMPOSITIONS ET TRAITEMENTS DESTINES A INHIBER KINASE ET/OU HMG-COA REDUCTASE
申请人:PHARMIX CORP
公开号:WO2007051065A2
公开(公告)日:2007-05-03
[EN] The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting ?38aMAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention. [FR] La présente invention concerne des compositions de matière, des ensembles et des procédés d'utilisation de ceux-ci dans le traitement de maladies liées à MAP-kinase et/ou de maladies liées à HMG-CoA réductase. L'invention concerne notamment des compositions de traitement de maladies inflammatoires et/ou cardiovasculaires chez un sujet animal, par inhibition de ?38aMAP kinase et/ou de HMG-CoA réductase, ainsi que par mise en oeuvre de formulations et de modes d'administration de ces compositions. L'invention concerne par ailleurs des procédés de conception rationnelle d'inhibiteurs de MAP-kinase et/ou de HMG-CoA réductase pour une utilisation selon l'invention.
WO2007/51065
申请人:——
公开号:——
公开(公告)日:——
COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE
申请人:Griffin John
公开号:US20090227602A1
公开(公告)日:2009-09-10
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38αMAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.